Rates of antipsychotic polytherapy have risen dramatically over several decades and have been reported in all treatment settings in many different countries. In addition, rigorously controlled studies have found antipsychotic polytherapy increases side effects and cost without improving primary outcome measures. Improvements on secondary measures have been reported by a few studies. Without supporting data, the increasing rates of antipsychotic polytherapy are coming under increased scrutiny.
